Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $143.77, giving the company a market capitalization of 178.5B. It carries a P/E multiple of 21.20 and pays a dividend yield of 2.2%.
On 2026-02-27, Gilead Sciences(GILD) stock moved within a range of $143.09 to $146.76. With shares now at $143.77, the stock is trading +0.5% above its intraday low and -2.0% below the session's peak.
Trading volume for Gilead Sciences(GILD) stock has reached 7.71M, versus its average volume of 7.07M.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
The stock's 52-week range extends from a low of $93.37 to a high of $157.29.
GILD News
Analyst Michael Yee of UBS maintained a Buy rating on Gilead Sciences, retaining the price target of $175.00. Michael Yee has given his Buy rating due to a com...
Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers. The acquisition adds...
Gilead (GILD) Sciences announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigatio...
Analyst ratings
72%
of 32 ratingsMore GILD News
Arcellx Inc. (NASDAQ:ACLX) shares rose on Wednesday after Gilead Sciences Inc. (NASDAQ:GILD) agreed to acquire the company for $7.8 billion, or $115 per share i...
Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Gilead Sciences and keeping the price target at $162.00. Tazeen Ahmad has given...
Arcellx Inc ( (ACLX) ) has shared an update. On February 22, 2026, Arcellx entered into a definitive merger agreement under which Gilead Sciences will acquire...
Close Key Takeaways Shares of biotech Arcellx vaulted higher Monday, lifted by news that it agreed to be acquired by Gilead. Monday's jump, of about 80%, in A...
Gonzalo Fuentes/Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET...
Arcellx (ACLX) stock rocketed higher on Monday after the clinical-stage biotechnology company announced an agreement with biopharmaceutical company Gilead Scien...
Advertisement What recent performance tells you about Gilead Sciences (GILD) Gilead Sciences (GILD) has drawn attention after a strong run, with the stock up...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.